U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H29ClN6O5
Molecular Weight 528.988
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-0424

SMILES

CC(C)OC1=C2C(NC3=C(Cl)C=NC4=C3OCO4)=NC=NC2=CC(OCCN5CCN(CC5)C(C)=O)=C1

InChI

InChIKey=MVWATCATLSSVBH-UHFFFAOYSA-N
InChI=1S/C25H29ClN6O5/c1-15(2)37-20-11-17(34-9-8-31-4-6-32(7-5-31)16(3)33)10-19-21(20)24(29-13-28-19)30-22-18(26)12-27-25-23(22)35-14-36-25/h10-13,15H,4-9,14H2,1-3H3,(H,27,28,29,30)

HIDE SMILES / InChI
Molecular Formula C25H29ClN6O5
Molecular Weight 528.988
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

AZD0424, a dual selective Src/Abl kinase inhibitor that has shown evidence of anti-tumor activity in pre-clinical studies. AZD0424 participated in phase I clinical trials in patients with advanced solid tumors, but this study was terminated because of insufficient evidence of efficacy as monotherapy.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
2015-04
Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.
2007-10
Patents

Patents

07462623
1
20060122199
1

Sample Use Guides

In Vivo Use Guide
AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:27:38 GMT 2025
Edited
by admin
on Mon Mar 31 23:27:38 GMT 2025
Record UNII
642PS51324
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD0424
Preferred Name English
AZD-0424
Common Name English
7-(2-(4-ACETYLPIPERAZIN-1-YL)ETHOXY)-4-(5-CHLORO-2,3-METHYLENEDIOXYPYRIDIN-4-YLAMINO)-5-ISOPROPOXYQUINAZOLINE
Systematic Name English
PIPERAZINE, 1-ACETYL-4-(2-((4-((6-CHLORO-1,3-DIOXOLO(4,5-B)PYRIDIN-7-YL)AMINO)-5-(1-METHYLETHOXY)-7-QUINAZOLINYL)OXY)ETHYL)-
Systematic Name English
ETHANONE, 1-(4-(2-((4-((6-CHLORO-1,3-DIOXOLO(4,5-B)PYRIDIN-7-YL)AMINO)-5-(1-METHYLETHOXY)-7-QUINAZOLINYL)OXY)ETHYL)-1-PIPERAZINYL)-
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C102976
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
FDA UNII
642PS51324
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545177
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
CAS
692054-06-1
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
DRUG BANK
DB13088
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
PUBCHEM
9893171
Created by admin on Mon Mar 31 23:27:38 GMT 2025 , Edited by admin on Mon Mar 31 23:27:38 GMT 2025
PRIMARY
Related Record Type Details
BCR-ABL KINASE
TARGET -> INHIBITOR
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966